Zobrazeno 1 - 10
of 52
pro vyhledávání: '"R. L. Murphy"'
Publikováno v:
Glia.
Autor:
R. L. Murphy, D. R. Woerner, I. Geornaras, J. N. Martin, H. Yang, J. N. Sofos, R. J. Delmore, K. E. Belk
Publikováno v:
Meat and Muscle Biology. 1:124-124
Publikováno v:
Crop Science. 41:1390-1395
The rate and duration of grain fill period has been shown to be associated with increased yield in cereals when water deficits occur during maturation. Grain fill duration can be approximated as the time between heading date and physiological maturit
Publikováno v:
Child's Nervous System. 22:632-634
The authors report a case of three brothers. Two of these siblings presented with congenital growth hormone deficiency and Chiari I malformation. The third and younger brother has been found not to have growth hormone deficiency or the Chiari I malfo
Autor:
S, Lambert-Niclot, N, Machouf, G, Peytavin, C, Soulie, M, Wirden, A, Simon, R L, Murphy, C, Katlama, R, Thomas, V, Calvez, A G, Marcelin
Publikováno v:
HIV medicine. 11(10)
Studies have shown the importance of having a high protein-binding-adjusted inhibitory quotient (IQ) for protease inhibitors (PIs) boosted with ritonavir. The objective of this study was to explore the virological response when combination atazanavir
Autor:
R S, Tubbs, R L, Murphy, J B, Golden, B, Etheridge, J C, Wellons, J P, Blount, E G, Salter, W J, Oakes
Publikováno v:
Folia morphologica. 64(4)
Data for the force necessary to fracture the isolated calvaria (skull cap) are not available in the extant literature. Twenty dry adult calvaria were tested to failure quasistatically at the vertex using a 15-kN load cell. The forces necessary to fra
Autor:
R L, Murphy
Publikováno v:
Antiviral therapy. 4
Preliminary results are presented from a dose-comparison trial of the regimen stavudine/lamivudine plus the novel protease inhibitor, ABT-378/ritonavir, given to 101 antiretroviral-naive, human immunodeficiency virus (HIV)-infected subjects foror = 2
Autor:
R L, Murphy
Publikováno v:
AIDS clinical care. 9(10)
Nonnucleoside transcriptase inhibitors (NNRTIs) are potent antiretroviral agents that can successfully be used in appropriate HIV/AIDS triple-therapy regimens, although resistance can develop rapidly. The two primary advantages of initiating NNRTIs t
Autor:
R L, Murphy
Publikováno v:
AIDS clinical care. 11(5)
This first installment of a two-part article on new antiretroviral drugs in development provides information on seven new protease inhibitors (PIs). The results of in vitro and in vivo trials are provided. Researchers hope these drugs will be more po
Autor:
R L, Murphy
Publikováno v:
AIDS clinical care. 11(6)
The second installment, of a two-part article on new antiretroviral drugs in development, provides information on five nucleoside and four nonnucleoside reverse transcriptase inhibitors. In addition, two new classes of drugs, fusion inhibitors and in